Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

Table 1 Demographic and clinical baseline characteristics of all 72 patients included in the study n (%)

Characteristic
Anti-TNFα therapy
IFX only	35 (48.6)
ADA only	17 (23.6)
IFX and ADA	15 (20.8)
ADA and IFX	5 (6.9)
Demographic characteristics
Gender (female:male)	39: 33
Age at start of treatment (median; range) (yr)	33 (15-71)
Disease extent according to Montréal classification, n (E1:E2:E3)	5:32:35
Duration of disease at start of anti-TNFα therapy, median (range) (mo)	69.5 (2-480)
Presence of at least one extraintestinal manifestation	30 (41.7)
Smoking status, n (active smokers:non-smokers:ex-smokers)	6:54:5 (n = 65)
BMI, median (range) (kg/m2)	24.1 (17.3-61.9) (n = 69)
Family history of IBD (n positive: n negative)	5:18 (n = 23)
History of colitis medication prior to start of anti-TNFα treatment
Steroids	70 (97.2)
Oral budesonide	21 (29.2)
5-ASA	66 (91.7)
Azathioprine	55 (76.4)
6-Mercaptopurine	3 (4.2)
Methotrexate	12 (16.7)
Tacrolimus	4 (5.6)
Cyclosporine	4 (5.6)
Medications concomitant with IFX therapy at start of therapy (n = 55)
Steroids	37 (67.3)
Oral budesonide	16 (29.1)
5-ASA	35 (63.6)
Azathioprine	16 (29.1)
6-Mercaptopurine	1 (1.8)
Methotrexate	3 (5.5)
Tacrolimus	1 (1.8)
Cyclosporine	0
Medications concomitant with ADA therapy at start of therapy (n = 37)
Steroids	25 (67.6)
Oral budesonide	10 (27.0)
5-ASA	28 (75.7)
Azathioprine	11 (29.7)
6-Mercaptopurine	0 (0)
Methotrexate	1 (2.7)
Tacrolimus	0 (0)
Cyclosporine	0 (0)

ADA: Adalimumab; 5-ASA: 5-Aminosalicylic acid; BMI: Body mass index; IBD: Inflammatory bowel disease; IFX: Infliximab, TNFα: Tumor necrosis factor alpha.